Clinical trials

  • L-LYSINE HYDROCHLORIDE; L-ARGININE HYDROCHLORIDE for Somatostatin receptor-positive solid tumours|Neuroendocrine tumour|Neuroblastoma|Rhabdomyosarcoma|Ewing's sarcoma|Gastrointestinal stromal tumour|Central nervous system neoplasm|Lymphoma
  • REPOTRECTINIB for Advanced solid tumors
  • sertraline for Anorexia nervosa
  • Chimeric locked nucleic acid and ribonucleic-deoxyribonucleic antisense oligonucleotide specific for the human UBE3A-antisense transcript (active substance listed as a nucleic acid ASO; productSubstances/substanceOrigin: Nucleic Acid) for Angelman syndrome
  • BI 765063 for Head and neck squamous cell carcinoma | Hepatocellular carcinoma
  • 2'-O-(2-METHOXYETHYL) MODIFIED ANTISENSE OLIGONUCLEOTIDE TARGETING UBE3A ANTISENSE TRANSCRIPT RNA for Angelman syndrome
  • Pancreas powder (pancreatin) for Pancreatic exocrine insufficiency | Post-pancreatectomy pancreatic exocrine insufficiency
  • AAVANC80-5'HOTOF, AAVANC80-3'HOTOF for Sensorineural hearing loss due to OTOF (otoferlin) mutations
  • EXS73565 for Chronic lymphocytic leukemia|Richter's transformation|Mantle cell lymphoma|Diffuse large B-cell lymphoma|Follicular lymphoma|Marginal zone lymphoma
  • TX200-TR101 for Kidney transplant rejection
  • RP2 for Solid tumours
  • VSF1.01 for Hearing loss